跳至主要内容
临床试验/NCT00134303
NCT00134303已完成4 期

Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity

University Hospital, Ghent1 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2005年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
65
试验地点
1
主要终点
Number of patients with histological amelioration of NASH after a period of 1 year

研究概览

简要总结

This is a comparison of metformin versus placebo in NASH patients receiving bariatric surgery for obesity.

详细描述

In patients receiving bariatric surgery, a preoperative liver biopsy will confirm the presence of NASH. Those patients with NASH (histologically defined according the Brunt's criteria) will be randomized to receive metformin (2 times 850 mg orally daily) or placebo for a time period of 1 year. A control liver biopsy will be performed after one year.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients receiving bariatric surgery for obesity

排除标准

  • Other causes of liver disease (hepatitis B virus [HBV], hepatitis C virus [HCV], primary biliary cirrhosis [PBC], etc.)
  • Patients with diabetes type I
  • Patients with endocrinological reasons for obesity (eg. Cushing, etc.)

研究组 & 干预措施

NASH

Experimental

干预措施: Metformin (Drug)

结局指标

主要结局

Number of patients with histological amelioration of NASH after a period of 1 year

时间窗: 1 year

次要结局

  • Number of patients with normalisation of ALT, steatosis on ultrasound after a period of 1 year(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验